RELMADA THERAPEUTICS, INC. — Director's Dealing 2019

Dec 23, 2019

SEC Form 3 — Initial Statement of Beneficial Ownership

Issuer: RELMADA THERAPEUTICS, INC. (RLMD)
CIK: 0001553643
Period of Report: 2019-12-19

Reporting Person: SCHMIDT ERIC THOMAS (Director)

Holdings (Non-Derivative)

Security	Shares	Ownership
Common Stock	55000	Direct

Holdings (Derivative)

Security	Exercise Price	Expiration	Underlying	Shares	Ownership
Options to purchase common stock	$43.47	2029-12-19	Common Stock (200000)		Direct
Options to purchase common stock	$9.00	2024-05-14	Common Stock (12500)		Direct
Options to purchase common stock	$6.00	2023-12-03	Common Stock (32500)		Direct

Footnotes

F1: Options granted on December 19, 2019 to purchase an aggregate of 200,000 shares of common stock. A total of 25% of the options will vest one year from the grant date, and the remaining 75% shall vest in equal quarterly increments of 6.25% of the initial option grant over the following three year period.